J Mult Scler Neuroimmunol.  2023 Jun;14(1):24-33. 10.59578/jmsni.2023.14.1.24.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review

• Kwon YN
• Kim SM

• KMID: 2561974
• DOI: http://doi.org/10.59578/jmsni.2023.14.1.24

Abstract

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system that is distinct from multiple sclerosis and neuromyelitis optica spectrum disorder. While an international consensus has recently been established regarding the clinical features and diagnostic criteria of MOGAD, further studies are needed to improve our understanding of the disease, including its treatment and prognosis. Accurate diagnostic methods and a comprehensive understanding of the clinical features are crucial, as test results must be integrated with clinical considerations. Currently, there is a lack of randomized controlled clinical trials on the treatment of MOGAD, but observational studies suggest that immunotherapy may be effective. This review aims to provide a comprehensive overview of the pathophysiology, clinical features, and recently established diagnostic criteria of MOGAD, as well as available treatment options, and prognosis.

Keyword

Myelin-oligodendrocyte glycoprotein; Demyelinating diseases; Autoimmune disease; Diagnosis; Therapeutics